Adaptive Biotechnologies Executes Lease for New 100,000 Square Foot Corporate Headquarters, Tripling its Footprint in Seattle...
August 07 2019 - 8:30AM
Adaptive Biotechnologies Corporation (Nasdaq:ADPT), a
commercial-stage biotechnology company that reads and translates
the genetic code of the adaptive immune system with the goal of
developing personalized diagnostics and therapeutics to improve
patient lives, today announced plans to lease a new corporate
headquarters with a state-of-the-art office space and research
facility that will triple the company’s Seattle footprint.
Adaptive has signed a 12-year, full-building, 100,000 square foot
lease with long-time partner Alexandria Real Estate Equities, Inc.
at 1165 Eastlake Avenue East, in the heart of Seattle’s Lake Union
life science cluster.
“We have worked with Alexandria to design a state-of-the-art
headquarters that will allow us to expand our lab capacity, R&D
footprint, and office space to help realize our goal to translate
the genetics of the adaptive immune system into clinical products
that we believe will transform medicine and improve patients’
lives,” said Chad Robins, chief executive officer and co-founder of
Adaptive. “This space will support Adaptive’s strategic growth
trajectory, provide our current and future employees with improved
space and amenities, and foster our mission-driven culture that
drives commitment to each other, our customers, and our
patients.”
Adaptive’s current headquarters, 1551 Eastlake Avenue East, also
part of The Eastlake Life Science Campus by Alexandria, is a short
distance from the future facility. Shell construction of the new
building is expected to be completed in 2020 and Adaptive plans to
occupy the new building in 2021 once interior construction is
finished. Over the past decade, Adaptive has focused on building
their proprietary immune medicine platform, clinical immunomics
database and infrastructure. The company is experiencing
significant growth as it transitions to leveraging the platform
towards developing truly personalized, patient-specific,
immune-driven clinical products.
“1165 Eastlake will provide Adaptive with a dynamic headquarters
necessary to support the needs of a rapidly growing company that
sits at the intersection of life science and technology,” said Joel
S. Marcus, executive chairman and founder of Alexandria Real Estate
Equities, Inc. and Alexandria Venture Investments. “Alexandria has
deep roots in the life science community in Seattle, and we
understand the unique needs of a company like Adaptive scaling to
achieve their mission to transform medicine.”
About Adaptive Biotechnologies Adaptive
Biotechnologies is a commercial-stage biotech company focused on
harnessing the inherent biology of the adaptive immune system to
transform the diagnosis and treatment of disease. We believe the
adaptive immune system is nature’s most finely tuned diagnostic and
therapeutic for most diseases, but the inability to decode it has
prevented the medical community from fully leveraging its
capabilities. Our proprietary immune medicine platform reveals and
translates the massive genetics of the adaptive immune system with
scale, precision and speed to develop products in life sciences
research, clinical diagnostics, and drug discovery. We have two
commercial products, and a robust clinical pipeline to diagnose,
monitor and enable the treatment of diseases such as cancer,
autoimmune conditions and infectious diseases. Our goal is to
develop and commercialize immune-driven clinical products tailored
to each individual patient. For more information, please visit:
adaptivebiotech.com.
Caution Regarding Forward-Looking
StatementsThis press release may contain forward-looking
statements regarding Adaptive’s current expectations, including its
ability to read and translate the genetic code of the adaptive
immune system to develop personalized diagnostics and therapeutics
to improve patient lives. Words such as “may,” “believe,”
“expect,” “estimate,” “predict,” or similar expressions, or
statements regarding intent, belief, or current expectations are
forward-looking statements.
These statements are not guarantees of future performance and
are subject to certain risks, uncertainties and assumptions that
are difficult to predict. Factors that could cause actual results
to differ include, but are not limited to, those described more
fully in the section captioned “Risk Factors” in the final
prospectus related to the public offering filed with the Securities
and Exchange Commission. Forward-looking statements contained in
this announcement are made as of this date, and Adaptive
Biotechnologies undertakes no duty to update such information
except as required under applicable law.
MEDIA CONTACT:Beth KeshishianDirector,
Corporate Communications 917-912-7195media@adaptivebiotech.com
INVESTOR CONTACT:Lynn Lewis or Carrie
Mendivil415-937-5405investors@adaptivebiotech.com
Adaptive Biotechnologies (NASDAQ:ADPT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Adaptive Biotechnologies (NASDAQ:ADPT)
Historical Stock Chart
From Apr 2023 to Apr 2024